Stock Information
symbol line chart

CRSPCRISPR Therapeutics AG

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Samarth Kulkarni

Location

N/A, Switzerland

Exchange

Nasdaq

Website

https://crisprtx.com

Summary

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases.

Company Info

CEO

Samarth Kulkarni

Location

N/A, Switzerland

Exchange

Nasdaq

Website

https://crisprtx.com

Summary

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases.

AI Insights for CRSP
2 min read

Quick Summary

CRISPR Therapeutics AG is a leading biotechnology company specializing in the development of gene-based medicines using CRISPR/Cas9 gene-editing technologies. Its business focuses on creating transformative therapies for serious diseases, particularly those with significant unmet medical need, such as blood disorders and cancer. The company’s primary business activities include advanced clinical research, drug development, and commercialization in collaboration with both academic and industry partners. CRISPR’s main customers are patients suffering from genetic diseases like sickle cell disease and beta-thalassemia, as well as healthcare providers and hospitals seeking novel therapies. Through strategic partnerships, especially with companies like Vertex Pharmaceuticals, CRISPR is contributing to a rapidly evolving gene-editing ecosystem.

The Bull Case

  • CRISPR Therapeutics boasts pioneering technology as one of the first to bring gene-editing therapies to market.
  • Its partnership with Vertex Pharmaceuticals provides financial resources, commercialization know-how, and shared risk for its flagship product, Casgevy.
  • The company holds a strong cash position, estimated at around $2 billion in liquid assets and no debt, affording it significant runway to fund further research and commercialization.
  • The approval and launch of Casgevy validate CRISPR’s platform and open doors for future gene-editing products.
  • CRISPR also benefits from a robust clinical pipeline with multiple assets in both oncology and rare diseases.

The Bear Case

  • Despite its technological strength, CRISPR Therapeutics remains unprofitable and faces significant R&D and commercialization expenses, which contribute to its widening net losses.
  • The company’s reliance on the success of Casgevy and a limited product portfolio exposes it to high concentration risk.
  • Early sales adoption for Casgevy has been slow, reflecting challenges in cost, complexity, and reimbursement.
  • Execution risk is high given the novel nature of its therapies and the complexities involved in manufacturing and delivering gene-editing products.
  • Competition from larger biotech firms and newer entrants also remains a persistent threat.

Key Risks

  • The primary risks facing CRISPR Therapeutics include clinical trial failures, unforeseen safety issues, and regulatory setbacks with its advanced therapies.
  • The company faces stiff competition from both established pharmaceutical firms and agile biotechs developing similar gene-editing or gene therapy solutions.
  • High costs of development, manufacturing, and delivery threaten long-term profitability, particularly if sales fall short of expectations.
  • Market adoption rate is uncertain due to the novelty, complexity, and cost of gene-editing treatments.

What to Watch

UpcomingIn the most recent quarter, CRISPR Therapeutics saw increased attention due to the commercial rollout of Casgevy, following regulatory approval for treating sickle cell disease and beta-thalassemia.
UpcomingThe company’s revenue modestly rose, but its net loss widened significantly due to higher R&D and commercialization expenses.
UpcomingThere were important updates on pipeline candidates, particularly the CAR-T and in vivo gene-editing programs, generating positive momentum for the stock.
ExpectedFor the coming quarter, analysts predict rising Casgevy sales as more treatment centers are established and patient uptake improves.

Price Drivers

  • CRISPR Therapeutics’ stock price is primarily driven by the success of its clinical trials and regulatory approvals, especially for its flagship gene-editing treatments like Casgevy.
  • The pace of adoption and sales of recently approved therapies, partnerships (such as with Vertex), market perception regarding the size of the addressable market, and updates on investigational pipeline progress are major catalysts.
  • Earnings reports, particularly top-line growth or widening losses, have significant influence, as does investor sentiment around biotechnology innovation and broader macroeconomic trends.
  • Regulatory policy shifts, reimbursement developments, and competitive advancements within the gene-editing space also impact valuation.

Recent News

  • Recent news highlights include the slow but accelerating adoption of Casgevy after its groundbreaking FDA approval for sickle cell disease and beta-thalassemia.
  • Several reports note the company’s widened quarterly net loss despite solid financial reserves and the ongoing strength of its clinical pipeline.
  • Analyst sentiment is generally bullish, with several predicting large upside potential if adoption rates improve and pipeline assets succeed, though others are cautious due to ongoing losses and competition.
  • CRISPR’s partnership with Vertex is consistently portrayed as a stabilizing force, with both companies expected to benefit from profit-sharing as Casgevy gains traction.

Market Trends

  • The broader market for gene-editing therapies is moving toward increased acceptance and growth, driven by regulatory approvals and higher visibility of CRISPR-based technologies.
  • There is a general risk-on sentiment among biotech investors interested in innovative treatment areas, although concerns about profitability and sustainability remain.
  • The competitive landscape is heating up as more companies bring advanced gene and cell therapies closer to commercialization.
  • Healthcare systems and payers are slowly adapting to accommodate reimbursement for one-time, high-cost, potentially curative treatments.

AI-generated summary. Not investment advice. DYOR.

Community Research

Research from investors like you

Be the first to share your analysis on CRSP

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@AntonioMyers 2 months ago

Biotech Breakthroughs: Betting on Cures or Chronic Care?

Biotech Breakthroughs: Betting on Cures or Chronic Care?

CRISPR Therapeutics   vs. Amgen : one is pioneering gene-editing cures while the other dominates long-term biologics. If you had to choose a biotech play for the next decade, do you lean toward cutting-edge innovation or proven commercial scale?

avatar
@JaneWilliams 2 months ago

Biotech Is Acting Wild.... Anyone Else Noticing???

Biotech Is Acting Wild.... Anyone Else Noticing???

Biotech has been confusing me lately ngl.   is trying so hard to prove it’s not just a pandemic one-hit wonder, and is basically carrying the whole sector on its Ozempic/Wegovy energy while everything else moves in slow motion. And then there’s popping off every time someone mentions gene editing like it’s sci-fi becoming real. I can’t tell if biotech is low-key setting up for a glow-up or if we’re all just coping through the volatility. Anyone else watching this space? Are you buying dips or waiting till the sector stops acting like a reality show?

avatar
@JaneWilliams 3 months ago

Why I'm Getting Interested in Biotechnology Stocks

Why I'm Getting Interested in Biotechnology Stocks

Lately I’ve been diving into biotech, and honestly, it feels like one of those sectors that’s too important to ignore. Biotech isn’t just about investing for profits. it’s about being part of the future of healthcare, although the main moto is profit only😶‍🌫️.

For me, it’s necessary to invest here because biotech doesn’t move exactly with the economy. Cause people need medicine in every market cycle, which gives my portfolio a little stability and maybe long-term growth potential. Plus, one breakthrough drug and boom it could completely change a company’s value.

As a new investor, the safest way to start is by mixing stability with innovation.

So, these are the companies I'm currently looking at

  strong, stable biotech leader

consistently growing with real products
major player in antivirals
  big in mRNA technology

  gene-editing pioneer (higher risk)

For me Biotech kinda risky yet interesting. So,what do you guys think?

No more topics to show